LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTNASDAQ🏆 #1879 by market capEarnings Nov 12US Equity
$32.08▲ $0.29 (+0.91%)
Pre-market · at closeTrack LKFT
Get earnings, price moves & breaking news on Telegram
24h▲ 0.9%
7d▲ 2.2%
14d▲ 7.3%
30d▲ 8.5%
ytd▼ 1.8%
1y▲ 3.7%
🏦Market Cap
$2.10B
Small Cap
📈Revenue Growth (YoY)
303.5%
High Growth
📊Gross Margin
98.0%
High
💵FCF Margin
-28.9%
Thin
⚖️P/S Ratio
1.8x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $31.53 – $32.39
- 52-Week Range
- $25.68 – $36.24
- Volume (shares)
- 11,439
- Avg Volume (shares)
- —
- Shares Outstanding
- 65.5M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $1.11B
- Last Q Revenue
- —
- P/E Ratio
- 3.8
- P/S Ratio
- 1.8x
- EPS (TTM)
- $7.42
- Dividend Yield
- 0.00%
LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout LAKEFRONT BIOTHERAPEUTIC-ADR
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.